JAZZ Q1 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$902M+1.0% YoY

Gross Profit

$806M89.4% margin

Operating Income

$66M7.3% margin

Net Income

-$15M-1.6% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-10.9%

Cash Flow

Operating Cash Flow

$267M

Free Cash Flow

$260M

Stock-Based Comp.

$61M

Balance Sheet

Total Assets

$11.3B

Total Liabilities

$7.6B

Stockholders' Equity

$3.7B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$902M	$893M	+1.0%
Gross Profit	$806M	$764M	+5.5%
Operating Income	$66M	$126M	-47.5%
Net Income	-$15M	$69M	-121.1%

Revenue Segments

Xywav

$315M35%

Epidiolex/Epidyolex

$199M22%

Rylaze/Enrylaze

$103M11%

Zepzelca

$75M8%

Xyrem

$64M7%

High Sodium AG Oxybate Product Royalty Revenue

$50M6%

Defitelio/Defibrotide

$48M5%

Vyxeos

$32M4%

Other Royalty And Contract Revenues

$10M1%

Other Products

$4M0%

Sativex

$3M0%

Geographic Segments

UNITED STATES

$808M90%

Europe

$71M8%

Other Countries

$22M2%